KiteLock 4% is an Antimicrobial
Bloodstream infections occur in patients with central venous catheters. KiteLock 4% has shown to decrease infection by over 70%  In the US, there are an estimated 250,000 CLABSIs, 33,000 associated deaths and billions of dollars in healthcare expenditures per year
KiteLock 4% is an Anticoagulant
A study of outcomes in 50,000 patients undergoing home infusion demonstrated that occlusions lead to therapy interruption caused by loss of patency (43%), device replacement (29%), device removal (14%), emergency room visits (9%), and unscheduled hospital visits (6%) 
Reduces occlusions up to 70%, catheter line replacement by 13%, which translates into considerable cost savings 
KiteLock 4% is Antibiofilm
The only non-antibiotic, antimicrobial solution with the capability to eradicate biofilm of all relevant bacterial strains and yeast including superbugs. (eg. MRSA, etc.). KiteLock 4% solution was effective at eradicating surface-attached bioﬁlms from Gram-positive, Gram-negative, and fungal species, to prevent bioﬁlm growth within CVADs and to eliminate established bioﬁlms. 
Safe for Children
Results demonstrate a significant decrease in CLABSI (100 %; p = 0.002) with KiteLock 4% in addition to a reduction (50%, p = 0.018) in catheter occlusions. Our preliminary findings suggest KiteLock is safe and effective in reducing CLABSI and catheter occlusions in pediatric patients with long-term central access requirements. 
Approved for use in children
Understanding the role of biofilm in vascular access
Biofilms, or colonies of bacteria growing on surfaces inside and outside of the body, have been around for billions of years and are everywhere.
Within twelve minutes of bacterial colonization, biofilm is produced. Within 24 hours, the interior of a central venous access device can be covered with biofilm. Biofilms are responsible for 80% of central line infections 
The dissemination of biofilm bacteria, particularly in clump formation, can also cause metastasizing infections including encephalitis, endocarditis, abscesses, etc.
Eighty years ago medicine was transformed by the development of antibiotics. They made deadly bacterial diseases that once killed millions effectively treatable and made other medical advances, like chemotherapy and organ transplants, possible. But bacteria are now pulling ahead in the game of survival of the fittest. We are entering a post-antibiotic era where we will be at risk from a simple infection because our antibiotics no longer work.
What is Antimicrobial Resistance (AMR)?
Antibiotic Resistance (AMR) happens when germs, like bacteria and fungi, develop the ability to defeat the drugs designed to kill them. Infections caused by antibiotic-resistant germs are difficult, and sometimes impossible, to treat. Antibiotic resistance does not mean the body is becoming resistant to antibiotics; it is that bacteria have become resistant to the antibiotics designed to kill them. These are also referred to as Superbugs.
How is SterileCare aligning to non-antibiotic antimicrobial resistance?
Non-antibiotic antimicrobial: by using KiteLock 4% infections are prevented and therefore the use of antibiotics is avoided
Lots of germs, few are drug resistant.
Antibiotics kill bacteria causing the illness as well as good bacteria protecting the body from infection.
The drug-resistant bacteria are now allowed to grow and take over.
Some bacteria give drug-resistance to other bacteria causing more problems
AMR is a slower-moving pandemic than COVID-19, but one that is worsening every day.